Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials
Sjögren's disease (SD) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of the exocrine glands, leading to the development of their destruction and progressive functional failure. The prevalence of SD is about 5%, which makes it one of the most common autoimmune d...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/998 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691621302468608 |
|---|---|
| author | A. V. Torgashina |
| author_facet | A. V. Torgashina |
| author_sort | A. V. Torgashina |
| collection | DOAJ |
| description | Sjögren's disease (SD) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of the exocrine glands, leading to the development of their destruction and progressive functional failure. The prevalence of SD is about 5%, which makes it one of the most common autoimmune diseases. SD often has a chronic, slowly progressing course.The paper discusses the results of international clinical trials of the efficiency of anti-B-cell therapy with rituximab (RTM) for glandular SD. It considers the impact of this therapy on various immunological, histological indicators, subjective and objective parameters of glandular function, and disease activity. Possible reasons for the discrepancy between the results of open-label clinical trials and randomized clinical trials, as well as predictors for the efficiency of RTM therapy are discussed.It has been found that RTM used to treat SD effectively reduces B-cell activity, improves the morphological pattern in the salivary glands and some extraglandular manifestations of the disease, and diminishes dryness and weakness. Anti-B-cell drugs have a great potential to treat SD. |
| format | Article |
| id | doaj-art-7f5162c3f91b4f8984e18d1d5a43c14c |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2020-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-7f5162c3f91b4f8984e18d1d5a43c14c2025-08-20T03:20:59ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-03-01141859210.14412/1996-7012-2020-1-85-922241Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trialsA. V. Torgashina0V.A. Nasonova Research Institute of RheumatologySjögren's disease (SD) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of the exocrine glands, leading to the development of their destruction and progressive functional failure. The prevalence of SD is about 5%, which makes it one of the most common autoimmune diseases. SD often has a chronic, slowly progressing course.The paper discusses the results of international clinical trials of the efficiency of anti-B-cell therapy with rituximab (RTM) for glandular SD. It considers the impact of this therapy on various immunological, histological indicators, subjective and objective parameters of glandular function, and disease activity. Possible reasons for the discrepancy between the results of open-label clinical trials and randomized clinical trials, as well as predictors for the efficiency of RTM therapy are discussed.It has been found that RTM used to treat SD effectively reduces B-cell activity, improves the morphological pattern in the salivary glands and some extraglandular manifestations of the disease, and diminishes dryness and weakness. Anti-B-cell drugs have a great potential to treat SD.https://mrj.ima-press.net/mrj/article/view/998sialadenitisrituximabanti-b-cell therapysjögren's diseasedry syndrome |
| spellingShingle | A. V. Torgashina Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials Современная ревматология sialadenitis rituximab anti-b-cell therapy sjögren's disease dry syndrome |
| title | Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials |
| title_full | Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials |
| title_fullStr | Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials |
| title_full_unstemmed | Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials |
| title_short | Efficacy of rituximab for glandular Sjö gren's disease according to international clinical trials |
| title_sort | efficacy of rituximab for glandular sjo gren s disease according to international clinical trials |
| topic | sialadenitis rituximab anti-b-cell therapy sjögren's disease dry syndrome |
| url | https://mrj.ima-press.net/mrj/article/view/998 |
| work_keys_str_mv | AT avtorgashina efficacyofrituximabforglandularsjogrensdiseaseaccordingtointernationalclinicaltrials |